Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
- 14 February 2017
- journal article
- review article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 37 (5) , 439-451
Abstract
Psoriasis is an inflammatory skin disease that affects 2–3% of the worldwide population. The interleukin-17 cytokine family has been proven to play a central role in the pathogenesis of psoriasis. Brodalumab is a novel biologic agent that targets interleukin-17 molecules and their receptors. We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework.Keywords
This publication has 38 references indexed in Scilit:
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011PLOS ONE, 2012
- Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled TrialJournal of Investigative Dermatology, 2012
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in PsoriasisNew England Journal of Medicine, 2012
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisNew England Journal of Medicine, 2012
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for PsoriasisNew England Journal of Medicine, 2012
- The Risk of Depression, Anxiety, and Suicidality in Patients With PsoriasisArchives of Dermatology, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008
- Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T CellsJournal of Investigative Dermatology, 2008
- Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with PsoriasisDermatology, 2006